These novel clonotypes were particularly found (approximately 50%) among CD8 T clones enriched in TIM-3, LAG-3, and CD103 markers, suggesting a recruitment of bystander and proximal CD8+ TRM into the tumor after ICPi therapy. This evidence concerns the gene HAVCR2 and neoplasm.